GILEAD SCIENCES, INC. for GILEAD SCIENCES INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| MICHAEL D BOYD | — |
| CHARLES M. CLAPTON | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Health Issues HCR
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| MICHAEL D BOYD | — |
| CHARLES M. CLAPTON | — |
| ANNA GRIFFIN | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Medicare/Medicaid MMM
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| MICHAEL D BOYD | — |
| CHARLES M. CLAPTON | — |
| ANNA GRIFFIN | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Copyright/Patent/Trademark CPT
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Budget/Appropriations BUD
Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| CHARLES M. CLAPTON | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Taxation/Internal Revenue Code TAX
Legislative and regulatory proposals to change international and domestic corporate tax law and policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.